FDA Warning Letters Do Not Prove Wrongdoing, Appeals Court Finds
Executive Summary
A state appeals court ruled that FDA warning letters are informal and advisory notifications and thus cannot be the basis of a finding that Johnson & Johnson made false and misleading statements to health care providers about Risperdal (risperidone) and Duragesic (fentanyl).
You may also be interested in...
Drug Literature Cases Raise First Amendment Issues
Litigation over the dissemination of scientific information at odds with FDA's instructions could define how the right to freedom of speech applies to marketing food and drug products.
Drug Literature Cases Raise First Amendment Issues
Litigation over the dissemination of scientific information at odds with FDA's instructions could define how the right to freedom of speech applies to marketing food and drug products.
Ingredients For Product Liability Litigation: From FDA Actions To Foreign Labels
What do plaintiffs lawyers look for in deciding whether to file a product liability suit against a pharmaceutical company?